#### SUMMARY OF PRODUCT CHARACTERISTICS

### 1. NAME OF THE MEDICINAL PRODUCT

A 313 200 000 UI POUR CENT, ointment

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

For the complete list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Ointment.

### 4. CLINICAL PARTICULARS

### 4.1 Therapeutic indications

Adjunctive treatment of irritant dermatitis.

## 4.2 Posology and method of administration

Apply topically 1 or 2 times per day.

### 4.3 Contraindications

- History of hypersensitivity to any of the components.
- Infected skin diseases.
- Oozing dermatitis.

## 4.4 Special warnings and precautions for use

The risk of hypervitaminosis A cannot be excluded in the case of prolonged application. Systemic effects (risk of hypervitaminosis) are to be feared when the topical application is repeated over a large area, under occlusion or thick layer, on an injured skin (in particular burned), on a mucous membrane, a skin of a premature baby and an infant or young child due to the surface/weight ratio and the spontaneous occlusion effect due to folds and diapers.

# 4.5 Interactions with other medicinal products and other forms of interactions

Not relevant.

### 4.6 Pregnancy and breast-feeding

### **Pregnancy:**

• Orally:

at high doses, the absence of epidemiological studies prevents a conclusion on the reality of the malformative risk. It is therefore not recommended to exceed 5000 IU per day (recommended daily intake).

• By dermal route:

The systemic passage of vitamin A from this topical form is negligible.

There are currently not enough exposed pregnancies to assess a possible effect of vitamin A administered dermally.

Therefore, the use of this drug should be considered during pregnancy only if necessary, avoiding simultaneous use of another drug containing vitamin A.

## **Breastfeeding:**

Do not apply to the breasts while breastfeeding because of the risk of ingestion of the product by the newborn.

## 4.7 Effects on ability to drive and use machines

Not relevant.

#### 4.8 Undesirable effects

Possible local allergic reaction to any of the components.

# **Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: French National Agency for Medicines and Health Products Safety (Ansm) and network of Regional Pharmacovigilance Centres. Web site: <a href="www.ansm.sante.fr">www.ansm.sante.fr</a>.

### 4.9 Overdose

Systemic passage has not been studied under the abnormal conditions of use described in Section 4.4. Special warnings and precautions for use.

The appearance of signs of hypervitaminosis A (nausea, headache, dizziness, dry skin, fatigue) should lead to discontinuation of treatment.

## 5. PHARMACOLOGICAL PROPERTIES

## 5.1 Pharmacodynamic properties

# **SKIN PROTECTION**

(D. Dermatology)

## **5.2 Pharmacokinetic properties**

Systemic passage of retinol under normal conditions of use is considered negligible.

## 5.3 Preclinical safety data

Not documented.

### 6. PHARMACEUTICAL PARTICULARS

### **6.1** List of excipients

Macrogol 400, macrogol 4000, polysorbate 80.

## **6.2 Incompatibilities**

Not applicable.

#### 6.3 Shelf life

30 months.

## 6.4 Special precautions for storage

Store at a temperature not exceeding 25°C.

### **6.5** Nature and contents of container

50 g in tube (Aluminium coated with an epoxyphenolic internal varnish) closed with a cap (Polypropylene).

## 6.6 Special precautions for disposal and handling

No particular requirements.

## 7. MARKETING AUTHORISATION HOLDER

PHARMA DEVELOPPEMENT CHEMIN DE MARCY 58800 CORBIGNY FRANCE

# 8. MARKETING AUTHORISATION NUMBER (S)

• 300 014-7: 50 g in tube (Aluminium).

# 9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION

Date of first authorisation: 12/03/1998

## 10. DATE OF REVISION OF THE TEXT

17/08/2009

### 11. DOSIMETRY

Not relevant.

## 12. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS

Not relevant.

## PRESCRIPTION AND SUPPLY CONDITIONS

This medicinal product is available without a prescription.